Has anyone else heard this rumor? This topic was explored about 10 years ago and it was decided it was too important a piece to the orthopedic portfolio. I'm now hearing in the field this is again being explored.
Haven’t heard the rumor but it makes sense. JNJ has shown remarkable patience with the Spine business. We generally move on from low/no growth businesses with shrinking margins pretty quickly.
Haven’t heard the rumor but it makes sense. JNJ has shown remarkable patience with the Spine business. We generally move on from low/no growth businesses with shrinking margins pretty quickly.
Yes this rumor is beginning to gain momentum in my territory too. One of my docs even brought this up to me after a case last week.
this would be a great move and smart for the business which sadly means its probably not happening. Spine has been an anchor on the business for far too long. Negative growth quarter over quarter and no innovation. The amount of money thats been poured into salvaging it has been insanity.
about *** time meanwhile, let's celebrate women of orthopedics let's spark allyship let's celebrate black women let's promote mediocrity anything and everything that is father away from sales and customer
Probably the only thing holding this up is how to message it the the BOD. The Spine business was a large component of the Synthes acquisition, admitting the Spine business isn’t cutting it will be a tough pill to swallow for the Gorsk.
Yeah, dogs tend to stay around too long when someone up high predicted it would be a WIN. They just keep dragging it along.
I don't disagree. However, all of us in spine knew that the Synthes deal was all about their trauma business and not spine, so i believe this idea of spinning off spine is very real.
True, the deal wasn’t really about Spine. But, the deal was for Trauma/CMF/Spine for 20B. Speaking from a valuation perspective, the Trauma business was worth 15B-17B, so we paid 3B-5B for 2 product lines we really didn’t want. Ouch. CMF was largely ignored from day 1 and it was apparent to me early on that Spine was a disaster. And let’s face, the Trauma/Recon “synergies” never materialized anywhere close to the level needed to justify the purchase price.
Anything New? Zimmer is spinning off it's Spine and Dental business into a new division. J&J thinking the same? My Allyship is leaking!
J&J should sell the device business. It’s a drag on earnings and destroys shareholder value. The enterprise is worth more without it.